Division of Pulmonary, Critical Care & Sleep Medicine

Roger Spragg, M.D.

Professor of Medicine Emeritus

Department of Medicine, UC San Diego

Medicine Service, San Diego VA Healthcare System

President, Veterans Medical Research Foundation Board

 

CLINICAL INTERESTS:

  1. Clinical instruction of PCCM fellows
  2. Scientific reviews in the area of acute lung injury

INVESTIGATIVE INTERESTS:

  1. Pathology of the surfactant system of the mature lung
  2. Mechanisms of acute lung injury

 

SELECTED PUBLICATIONS

  1. Rice TW, Wheeler AP, Thompson BT, deBoisblanc BP, Steingrub J, Rock P; NHLBI ARDS Clinical Trials Network. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA. 2011 12;306(14):1574-81.
  2. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Matthay MA, Brower RG, Carson S, Douglas IS, Eisner M, Hite D, Holets S, Kallet RH, Liu KD, MacIntyre N, Moss M, Shoenfeld D, Steingrub J, Thompson BT.  Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury.  Am Respir Critical Care Med. 2011 Sept 1;184(5):561-8
  3. Kerr KM, Auger WR, Marsh JJ, Devendra G, Spragg RG, Kim NH, Channick RN, Jamieson SW, Madani MM, Manecke GR, Roth DM, Shragg GP, Fedullo PF. Efficacy of Methylprednisolone in Preventing Lung Injury Following Pulmonary Thromboendarterectomy. Chest. 2011 Aug 11. [Epub ahead of print
  4. Spragg RG, Taut FJ, Lewis JF, Schenk P, Ruppert C, Dean N, Krell K, Karabinis A, Günther A. Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. Am J Respir Crit Care Med. 2011 Apr 15;183(8):1055-61.
  5. Calfee CS, Ware LB, Glidden DV, Eisner MD, Parsons PE, Thompson BT, Matthay, MA; National Heart, Blood, and Lung Institute Acute Respiratory Distress Syndrome Network. Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. Crit Care Med. 2011 Apr;39(4):711-7.
  6. Spragg RG, Masys DR, Sergeant D, Lawrie T, Taut FJ. An informatics strategy to assure enrollment criteria compliance in studies of the critically ill. Contemp Clin Trials. 2010 Nov;31(6):530-5. Epub 2010 Aug 4.
  7. Spragg RG, Bernard GR, Checkley W, Curtis JR, Gajic O, Guyatt G, Hall J, Israel E, Jain M, Needham DM, Randolph AG, Rubenfeld GD, Schoenfeld D, Thompson BT, Ware LB, Young D, Harabin AL. Beyond mortality: future clinical research in acute lung injury. Am J Respir Crit Care Med. 2010 May 15;181:1121-7.
  8. Ware LB, Koyama T, Billheimer DD, Wu W, Bernard GR, Thompson BT, Brower RG, Standiford TJ, Martin TR, Matthay MA; NHLBI ARDS Clinical Trials Network. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest. 2010 Feb;137(2):288-96.
  9. Calfee CS, Eisner MD, Parsons PE, Thompson BT, Conner ER Jr, Matthay MA, Ware LB; NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network. Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury. Intensive Care Med. 2009 Feb;35(2):248-57.
  10. Erickson SE, Shlipak MG, Martin GS, Wheeler AP, Ancukiewicz M, Matthay MA, Eisner MD; National Institutes of Health National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network. Racial and ethnic disparities in mortality from acute lung injury. Crit Care Med. 2009 Jan;37(1):1-6
  11. Taut FJ, Rippin G, Schenk P, Findlay G, Wurst W, Häfner D, Lewis JF, Seeger W, Günther A, Spragg RG. A Search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute). Chest. 2008 Oct;134(4):724-32.
  12. Spragg R. Surfactant for acute lung injury. Am J Respir Cell Mol Biol. 2007 Oct;37(4):377-8.
  13. Davidson WJ, Dorscheid D, Spragg R, Schulzer M, Mak E, Ayas NT. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis. Crit Care. 2006;10(2):R41.
  14. Lu Y, Song Z, Zhou X, Huang S, Zhu D, Yang C Bai X, Sun B, Spragg R; Shanghai ARDS Study Group. A 12-month clinical survey of incidence and outcome of acute respiratory distress syndrome in Shanghai intensive care units. Intensive Care Med. 2004 Dec;30(12):2197-203.
  15. Spragg RG, Lewis JF, Walmrath HD, Johannigman J, Bellingan G, Laterre PF, Witte MC, Richards GA, Rippin G, Rathgeb F, Häfner D, Taut FJ, Seeger W. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med. 2004 Aug 26;351(9):884-92.
  16. Spragg RG, Ponganis PJ, Marsh JJ, Rau GA, Bernhard W. Surfactant from diving aquatic mammals. J Appl Physiol. 2004 May;96(5):1626-32.
  17. Spragg RG, Lewis JF, Wurst W, Häfner D, Baughman RP, Wewers MD, Marsh JJ. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med. 2003 Jun 1;167(11):1562-6.
  18. Li J, Marsh JJ, Spragg RG. Effect of CTP:phosphocholine cytidylyltransferase overexpression on the mouse lung surfactant system. Am J Respir Cell Mol Biol. 2002 Jun;26(6):709-15.
  19. Spragg RG, Smith RM, Harris K, Lewis J, Häfner D, Germann P. Effect of recombinant SP-C surfactant in a porcine lavage model of acute lung injury. J Appl Physiol. 2000 Feb;88(2):674-81.
  20. Spragg RG, Li J. Effect of phosphocholine cytidylyltransferase overexpression on phosphatidylcholine synthesis in alveolar type II cells and related cell lines. Am J Respir Cell Mol Biol. 2000 Jan;22(1):116-24.
  21. Artigas A, Bernard GR, Carlet J, Dreyfuss D, Gattinoni L, Hudson L, Lamy M, Marini JJ, Matthay MA, Pinsky MR, Spragg R, Suter PM. The American-European Consensus Conference on ARDS, part 2: Ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling. Acute respiratory distress syndrome. Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1332-47.
  22. Hopkins SR, Schoene RB, Henderson WR, Spragg RG, West JB. Sustained submaximal exercise does not alter the integrity of the lung blood-gas barrier in elite athletes. J Appl Physiol. 1998 Apr;84(4):1185-9.
  23. Floros J, DiAngelo S, Koptides M, Karinch AM, Rogan PK, Nielsen H, Spragg RG, Watterberg K, Deiter G. Human SP-A locus: allele frequencies and linkage disequilibrium between the two surfactant protein A genes. Am J Respir Cell Mol Biol. 1996 Oct;15(4):489-98.
  24. Ahuja A, Oh N, Chao W, Spragg RG, Smith RM. Inhibition of the human neutrophil respiratory burst by native and synthetic surfactant. Am J Respir Cell Mol Biol. 1996 May;14(5):496-503.
  25. Pappert D, Gilliard N, Heldt G, Merritt TA, Wagner PD, Spragg RG. Effect of N-nitroso-N-methylurethane on gas exchange, lung compliance, and surfactant function of rabbits. Intensive Care Med. 1996 Apr;22(4):345-52.
  26. Chao W, Spragg RG, Smith RM. Inhibitory effect of porcine surfactant on the respiratory burst oxidase in human neutrophils. Attenuation of p47phox and p67phox membrane translocation as the mechanism. J Clin Invest. 1995 Dec;96(6):2654-60.
  27. Gilliard N, Pappert D, Spragg RG. Fractal analysis of surfactant deposition in rabbit lungs. J Appl Physiol. 1995 Mar;78(3):862-6.

PubMed:

Board Certified:

  • Internal Medicine
  • Pulmonary Medicine

VA Medical Center

To contact Dr. Spragg:  rspragg@ucsd.edu